Nanox Launches Artificial Intelligence Functionality in Second Opinions Platform

2 weeks ago

Nanox integrates FDA-cleared population health AI solutions into its Second Opinions service New AI capabilities available to patients who submit…

Carrick Therapeutics Establishes New Headquarters in Boston, Massachusetts

2 weeks ago

Appoints David Sutherland, CPA, as Vice President of Finance and ControllerBOSTON, June 05, 2024 (GLOBE NEWSWIRE) -- Carrick Therapeutics Inc.,…

Dr. Michael Dent Finances $1 Million to Drive HealthLynked’s Healthcare Transformation

2 weeks ago

Naples, FL, June 05, 2024 (GLOBE NEWSWIRE) -- via IBN -- HealthLynked Corp (OTCQB: HLYK), a leader in personalized healthcare…

Madrigal Pharmaceuticals to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

2 weeks ago

CONSHOHOCKEN, Pa., June 05, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) today announced that the company will participate…

Clene to Present at the Emerging Growth Conference

2 weeks ago

SALT LAKE CITY, June 05, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its…

Equip’s Second Annual Report Highlights First-Rate Patient Outcomes, Company Growth

2 weeks ago

Available to more than 110 million Americans of all ages, Equip’s wraparound program meets patients at every stage of treatmentSAN…

Bluejay Therapeutics Presents Positive Preliminary BJT-778 Data from Phase 2 Clinical Trial in Chronic Hepatitis D at EASL 2024 Congress

2 weeks ago

100% of treated patients in Arm 1 achieved virologic response by Week 28 Most patients also achieved ALT normalization and…

GeneType and Stayhealthy Announce Landmark Distribution Agreement for Revolutionary Multi-Risk Test

2 weeks ago

MELBOURNE, Australia, June 05, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader…

Astiva Health Summer Gala: An Inaugural Celebration

2 weeks ago

ORANGE, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- via IBN -- Astiva Health Inc., a fast-growing Medicare Advantage Prescription Drug…

VYNE Therapeutics Announces Dosing of First Subject in Phase 2b Vitiligo Trial of Novel BET Inhibitor VYN201

2 weeks ago

Trial will evaluate once-daily VYN201 gel in subjects with either active or stable nonsegmental vitiligo Top-line data from the 24-week…